XML 92 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Nature of Business - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Feb. 28, 2025
Oct. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Cash, cash equivalents and short-term investments     $ 18,700  
Net Income (Loss)     (13,700) $ (34,357)
Accumulated deficit     (159,764) (146,064)
Consideration Transferred     29,400  
Total operating expenses     24,204 38,075
Gross cash proceeds     27,905 $ 10,340
Loan Agreement | Subsequent Event        
Gross proceeds from loan agreement $ 10,000      
2024 Private Placement        
Gross proceeds from the private placement     20,400  
Net proceeds from private placement     19,000  
Commissions and other transaction expenses     $ 1,400  
2024 Follow On        
Gross cash proceeds   $ 10,200    
Transaction costs   900    
Net proceeds   $ 9,300    
CalciMedica        
Percentage of ownership of common stock     72.00%  
Graybug        
Percentage of ownership of common stock     28.00%  
Convertible Debt | 2024 Follow On        
Proceeds from issuance of convertible notes     $ 8,600  
Preferred Stock, Warrants and Common Stock | 2024 Private Placement        
Total net proceeds     $ 140,700